Premium
IS 1,25‐DIHYDROXY‐CHOLECALCIFEROL HARMFUL TO RENAL FUNCTION IN PATIENTS WITH CHRONIC RENAL FAILURE?
Author(s) -
CHRISTIANSEN C.,
RØDBRO P.,
CHRISTENSEN MERETE S.,
HARTNACK BIRGITTE
Publication year - 1981
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1981.tb00659.x
Subject(s) - chronic renal failure , medicine , microgram , renal osteodystrophy , renal function , cholecalciferol , endocrinology , creatinine , vitamin d and neurology , vitamin , urology , kidney disease , chemistry , biochemistry , in vitro
SUMMARY Seventeen undialysed adult patients with chronic renal failure took part in a controlled study of the effects of 1,25(OH) 2 D 3 and D 3 . After a 6‐month observation period the patients were allocated at random to two groups for 6 months of treatment with either 1,25(OH) 2 D 3 (mean dose 0·5 μg daily) or D 3 (dose 100 μg daily). Treatment was then discontinued and the patients were studied for a further 6 months. Serum iPTH was decreased in both groups but most markedly in the 1,25(OH) 2 D 3 group in which the iPTH values became normal. Serum creatinine increased during treatment in both groups. In the group receiving 1,25(OH) 2 D 3 this was coupled to an increase in serum calcium within the normal range. Our data demonstrate that 1,25(OH) 2 D 3 treatment in patients with chronic renal failure leads to a further reduction in renal function, which may be partially reversible. Physicians should therefore be reluctant to give vitamin D analogues to patients with chronic renal failure unless they have severe symptomatic renal osteodystrophy.